BiotechTube
Sift Biosciences

Sift Biosciences

Cambridge, United States· Est.
siftbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Sift Biosciences is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, Massachusetts, with operations in San Carlos, California. The company is pioneering a novel class of T-cell modulators derived from bacteria and viruses, aiming to harness pre-existing microbial immunity to fight cancer and autoimmunity. Its proprietary platform integrates AI-driven discovery with experimental immunology to identify peptides that activate memory T cells against disease targets. Spun out of UC Berkeley, the company is led by a team with deep expertise in computational biology, immunology, and drug development.

OncologyAutoimmune Diseases

Technology Platform

Proprietary AI-driven platform integrating metagenomics and high-throughput T-cell screening to discover microbially derived peptide T-cell modulators.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The platform addresses a core limitation in immunotherapy—the scarcity of disease-specific T cells—potentially unlocking treatments for solid tumors where current cell therapies fail.
Its focus on the microbiome-immune interface is a novel and rich source for discovery, applicable to both oncology and large autoimmune markets.
Success could position Sift as an attractive platform partner for large pharma companies.

Risk Factors

The novel scientific hypothesis of using microbial peptides to redirect T cells is unproven and carries significant technical risk, including potential for off-target immune activation.
As a preclinical platform company, it faces high validation risk and is dependent on raising capital in a competitive financing environment.
It operates in the crowded and fast-moving immunotherapy space against well-resourced competitors.

Competitive Landscape

Sift competes in the broad T-cell immunotherapy space, which includes developers of bispecific antibodies, CAR-T therapies, cancer vaccines, and TCR-based therapies. Its unique differentiation is its AI-driven mining of microbial data for immune modulators, a niche approach compared to competitors focused on human genome-derived targets. Key competitors include established biotechs and pharma with similar goals but different technological bases.

More companies in AI / Machine Learning →More companies in United States →